Joseph Charalel

Investor

2025

Biotech

Vice President

2024 - 2025

• Lead diligence on and help source new investment deals (Seed, Series A, B, C, PIPEs and public market purchases) • Support portfolio companies as a Board Observer. Work with management teams to refine company strategy and investment pitches for new financings. Held Board Observer seats at: Evommune, Avalyn Pharma, Fountain Therapeutics, Aptihealth, Encodia • Manage positions in public biotech portfolio companies including fundamental research, valuation, and investment recommendations • Aid strategic planning and provide UX feedback for firm’s data science effort; my work primarily focuses on business objectives, methods, data sources, and user experience

Senior Associate

2022 - 2023

Guest Lecturer

2023 - 2024

• Guest lecturer on valuation methodology - INDE 209: Analysis of Public Companies in the Life Sciences

Manager

2020 - 2021

• Experience driving cases across private equity, customer experience, healthcare, banking • Led teams on 15 total diligences across technology and healthcare sectors (mix of growth stage and LBO targets) including revenue projections, market outlook (TAM/SAM, overall market growth), competitive landscape analysis, and post-acquisition strategy for investor clients • Supported and trained junior consultants with increasing responsibility

Consultant

2018 - 2020

General Partner

2017 - 2018

• Equity partner and manager in small-cap biotech fund led by Stanford trainees

PhD Candidate in Genetics

2013 - 2018

• Perform research in the laboratory of Dr. Christina Curtis on the genetic and epigenetic basis of drug resistance in HER2+ breast cancers via multi-omic profiling. Focus on using genome-wide sequencing assays and machine learning to understand drug response using in vitro model systems and patient data. (2015-Present) • Researcher in the laboratory of Dr. Atul Butte (now at UCSF). Worked on in silico characterization of cancer cell lines as tumor models using publicly available omics data. (2014-2015)

Intern

2017 - 2018

• Performed due diligence to identify potential new investment opportunities and develop comprehensive thesis for a particular therapeutic area • Contributed to company analysis efforts which led to investment decisions • Led key opinion leader calls, analyzed primary research literature, analyst reports to develop comprehensive commercial and scientific view of the key opportunities in the space • Synthesized and presented findings to Longitude leadership

Consultant Intern

2017 - 2017

• Worked on agile transformation project for top ten pharmaceutical client • Accepted full time offer for 2018 consultant class in SF office

Research Assistant

2010 - 2013

• Performed research in the laboratory of Dr. Liza Pon on the role and mechanisms of mitochondrial dynamics (anchorage, fusion, and fission) in cellular aging to better understand human age-related diseases • Initiated new project defining the role of mitochondrial fusion and fission in mitochondrial inheritance • Supervised and mentored three undergraduate students • Established new techniques in the lab through literature search and new partnerships • Co-authored 3 papers (listed below)

Analyst Intern

2008 - 2008

• Synthesized research from secondary sources and investor conferences to contribute to investment decisions for a long-short equity hedge fund with ~$500M AUM